The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Open accessAbstract
Chromatin regulators have become attractive targets for cancer therapy, but it is unclear why inhibition of these ubiquitous regulators should have gene-specific effects in tumor cells. Here, we investigate how inhibition of the widely expressed transcriptional coactivator BRD4 leads to selective inhibition of the MYC oncogene in multiple myeloma (MM). BRD4 and Mediator were found to co-occupy thousands of enhancers associated with active genes. They also co-occupied a small set of exceptionally large super-enhancers associated with genes that feature prominently in MM biology, including the MYC oncogene. Treatment of MM tumor cells with the BET-bromodomain inhibitor JQ1 led to preferential loss of BRD4 at super-enhancers and consequent transcription elongation defects that preferentially impacted genes with super-enhancers, including MYC. Super-enhancers were found at key oncogenic drivers in many other tumor cells. These observations have implications for the discovery of cancer therapeutics directed at components of super-enhancers in diverse tumor types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“SEs in both HCC and TAN were associated with GO terms related to metabolic genes (e.g. CYP3A4, SLC38A4, and IGFBP1) (Fig. 2c)20,21,58.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [58]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Topological domains in mammalian genomes identified by analysis of chromatin interactions
Dixon, J. R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J. S., & Ren, B. (2012) · Nature · doi:10.1038/nature11082 · Cited by 6,829
Pruitt, K. D., Tatusova, T. A., & Maglott, D. R. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl842 · Cited by 4,441
Histone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
Self-citationSelective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Self-citationMaster Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Self-citationThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,767
Cabili, M. N., Trapnell, C., Goff, L. A., Koziol, M. J., Tazón‐Vega, B., Regev, A., & Rinn, J. L. (2011) · Genes & Development · doi:10.1101/gad.17446611 · Cited by 3,551
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,008
Extrachromosomal circular DNA: Current status and future prospects
Zhao, Y., Yu, L., Zhang, S., Su, X., & Zhou, X. (2022) · eLife · doi:10.7554/elife.81412 · Cited by 51
Ning, H., HUANG, S. H., Yang, L., Zhi, R., Yan, H., Jin, J., Hu, Z., Guo, K., Liu, J., Yang, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34253-1 · Cited by 53
Linking chromatin acylation mark-defined proteome and genome in living cells
Qin, F., Li, B., Wang, H., Ma, S., Li, J., Liu, S., Kong, L., Zheng, H., Zhu, R., Han, Y., et al. (2023) · Cell · doi:10.1016/j.cell.2023.02.007 · Cited by 55
Drugging Chromatin in Cancer: Recent Advances and Novel Approaches
Cai, S. F., Chen, C.-W. D., & Armstrong, S. A. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.042 · Cited by 50
Interplay Between Inflammation and Epigenetic Changes in Cancer
Maiuri, A. R., & O’Hagan, H. M. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.09.002 · Cited by 48
Lingering Questions about Enhancer RNA and Enhancer Transcription-Coupled Genomic Instability
Rothschild, G., & Basu, U. (2017) · Trends in Genetics · doi:10.1016/j.tig.2016.12.002 · Cited by 52
Gavai, A. V., Norris, D. J., Lucca, G. V. D., Tortolani, D. R., Tokarski, J. S., Dodd, D. S., O’Malley, D., Zhao, Y., Quesnelle, C. A., Gill, P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00625 · Cited by 51
Zheng, B., Aoi, Y., Shah, A. P., Iwanaszko, M., Das, S., Rendleman, E. J., Zha, D., Khan, N. H., Smith, E. R., & Shilatifard, A. (2021) · Genes & Development · doi:10.1101/gad.346106.120 · Cited by 50
Zhang, C., Zhao, N., Zhang, X., Xiao, J. Y., Li, J., Lv, D., Zhou, W., Li, Y., Xu, J., & Li, X. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa162 · Cited by 49
Sun, Y., Yan, K. H., Wang, Y., Xu, C., Wang, D., Zhou, W. Z., Guo, S., Han, Y., Tang, L., Shao, Y., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00408-8 · Cited by 48
Distal enhancers: new insights into heart development and disease
Wamstad, J. A., Wang, X., Demuren, O. O., & Boyer, L. A. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.10.008 · Cited by 48
Enhancer alterations in cancer: a source for a cell identity crisis
Kron, K. J., Bailey, S. D., & Lupien, M. (2014) · Genome Medicine · doi:10.1186/s13073-014-0077-3 · Cited by 49
Jacques, C., Lamoureux, F., Baud’huin, M., Calleja, L. R., Quillard, T., Amiaud, J., Tirode, F., Rédiní, F., Bradner, J. E., Heymann, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8214 · Cited by 52
Self-citationProliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling
Krämer, M., Ribeiro, D., Arsenian‐Henriksson, M., Deller, T., & Rohrer, H. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0183-16.2016 · Cited by 47
Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors
Ramadoss, M., & Mahadevan, V. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.011 · Cited by 51
Kim, S. R., Lewis, J. M., Cyrenne, B. M., Monico, P. F., Mirza, F. N., Carlson, K. R., Foss, F. M., & Girardi, M. (2018) · Oncotarget · doi:10.18632/oncotarget.25670 · Cited by 49
(+)-JQ1 attenuated LPS-induced microglial inflammation via MAPK/NFκB signaling
Wang, H., Huang, W., Liang, M., Shi, Y., Zhang, C., Li, Q., Liu, M., Shou, Y., Yin, H., Zhu, X., et al. (2018) · Cell & Bioscience · doi:10.1186/s13578-018-0258-7 · Cited by 49
Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer
Zhou, Y., Lu, L., Jiang, G., Chen, Z., Li, J., An, P., Chen, L., Du, J., & Wang, H. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0222-4 · Cited by 49
Endodermal Maternal Transcription Factors Establish Super-Enhancers during Zygotic Genome Activation
Paraiso, K. D., Blitz, I. L., Coley, M., Cheung, J., Sudou, N., Taira, M., & Cho, K. W. Y. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.013 · Cited by 49
Reece, A. S., & Hulse, G. K. (2019) · Epigenetics · doi:10.1080/15592294.2019.1633868 · Cited by 51
Bromodomain inhibitor JQ1 reversibly blocks IFN-γ production
Gibbons, H. R., Mi, D. J., Farley, V. M., Esmond, T., Kaood, M. B., & Aune, T. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-46516-x · Cited by 50
Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects
Gambacorta, V., Gnani, D., Vago, L., & Micco, R. D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00207 · Cited by 49
Zhang, F., Wu, Z., Chen, P., Zhang, J., Wang, T., Zhou, J., & Zhang, H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115228 · Cited by 49
Yoshino, S., Yokoyama, T., Sunami, Y., Takahara, T., Nakamura, A., Yamazaki, Y., Tsutsumi, S., Aburatani, H., & Nakamura, T. (2020) · Blood · doi:10.1182/blood.2019004586 · Cited by 50
The emerging role of BET inhibitors in breast cancer
Andrikopoulou, Α., Liontos, M., Koutsoukos, K., Dimopoulos, M. A., & Zagouri, F. (2020) · The Breast · doi:10.1016/j.breast.2020.08.005 · Cited by 51
Comparative analyses of super-enhancers reveal conserved elements in vertebrate genomesPreprint
Perez-Rico, Y. A., Boeva, V., Mallory, A. C., Bitetti, A., Majello, S., Barillot, E., & Shkumatava, A. (2016) · Genome Research · doi:10.1101/gr.203679.115 · Cited by 51
Emerging Implications of Phase Separation in Cancer
Ren, J., Zhang, Z., Zong, Z., Zhang, L., & Zhou, F. (2022) · Advanced Science · doi:10.1002/advs.202202855 · Cited by 48
BRD4: New hope in the battle against glioblastoma
Duan, W., Yu, M., & Chen, J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106767 · Cited by 49
Super-enhancers complexes zoom in transcription in cancer
Wang, M., Chen, Q., Wang, S., Xie, H., Liu, J., Huang, R., Xiang, Y., Jiang, Y., Tian, D., & Bian, E. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02763-5 · Cited by 51
Super-enhancers: Asset management in immune cell genomes
Witte, S. J., O’Shea, J. J., & Vahedi, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.07.005 · Cited by 46
Donato, E., Croci, O., Sabò, A., Müller, H., Morelli, M. J., Pelizzola, M., & Campaner, S. (2016) · Leukemia · doi:10.1038/leu.2016.182 · Cited by 52
Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model
Zhu, X., Enomoto, K., Zhao, L., Zhu, Y. J., Willingham, M. C., Meltzer, P. S., Qi, J., & Cheng, S.-Y. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0914 · Cited by 49
Hu, H., Shu, M., He, L., Yu, X., Liu, X., Lu, Y., Chen, Y., Miao, X., & Chen, X. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.457 · Cited by 50
Nakamura, A., Nakata, D., Kakoi, Y., Kunitomo, M., Murai, S., Ebara, S., Hata, A., & Hara, T. (2018) · Oncotarget · doi:10.18632/oncotarget.24414 · Cited by 50
Tarczewska, A., & Greb‐Markiewicz, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215306 · Cited by 49
Evolution and structure of clinically relevant gene fusions in multiple myeloma
Foltz, S. M., Gao, Q., Yoon, C. J., Sun, H., Yao, L., Li, Y., Jayasinghe, R. G., Cao, S., King, J. A., Kohnen, D. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16434-y · Cited by 48
Zhang, J., Ying, Y., Li, M., Wang, M., Huang, X., Jia, M., Zeng, J., Ma, C., Zhang, Y., Li, C., et al. (2020) · Theranostics · doi:10.7150/thno.47081 · Cited by 51
Huang, Z., Liang, N., Goñi, S., Damdimopoulos, A. E., Wang, C., Ballaire, R., Jager, J., Niskanen, H., Han, H., Jakobsson, T., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.12.040 · Cited by 52
Principe, D. R., Xiong, R., Li, Y., Pham, T. D., Kamath, S. D., Dubrovskyi, O., Ratia, K. M., Huang, F., Zhao, J., Shen, Z., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116764119 · Cited by 47
Zhou, R. W., Xu, J., Martin, T. C., Zachem, A. L., He, C., Ozturk, S., Demircioğlu, D., Bansal, A., Trotta, A. P., Giotti, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33377-8 · Cited by 49
Tian, R., Huang, Z.-Y., Li, L., Yuan, J., Zhang, Q., Meng, L., Lang, B., Hong, Y., Zhong, C., Tian, X., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad105 · Cited by 44
Gyurkó, D. M., Veres, D. V., Módos, D., Lenti, K., Korcsmáros, T., & Csermely, P. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.06.005 · Cited by 50
Li, J., Ma, J., Meng, G., Lin, H., Wu, S. L. Y., Wang, J., Luo, J., Xu, X., Tough, D. F., Lindon, M. J., et al. (2016) · Stem Cell Research · doi:10.1016/j.scr.2016.07.006 · Cited by 47
Tao, Z., Li, X., Wang, H., Chen, G., Feng, Z., Wu, Y., Yin, H., Zhao, G., Deng, Z., Zhao, C., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.181 · Cited by 47
Targeting Epigenetics in Lung CancerPreprint
Chao, Y. L., & Pecot, C. V. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a038000 · Cited by 49
Guo, L., Li, J., Zeng, H., Guzman, A. G., Li, T., Lee, M., Zhou, Y., Goodell, M. A., STEPHAN, C. C., Davies, P. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14604-6 · Cited by 47
Sakamoto, T., Batmanov, K., Wan, S., Guo, Y., Lai, L., Vega, R. B., & Kelly, D. P. (2022) · Nature Communications · doi:10.1038/s41467-022-29733-3 · Cited by 51
Recent progress and structural analyses of domain‐selective BET inhibitors
Divakaran, A., Harki, D. A., & Pomerantz, W. C. K. (2023) · Medicinal Research Reviews · doi:10.1002/med.21942 · Cited by 48
Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape
Nabet, B., Broin, P. Ó., Reyes, J. M., Shieh, K. R., Lin, C. Y., Will, C., Popovic, R., Ezponda, T., Bradner, J. E., Golden, A. A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.078 · Cited by 45
Self-citationZhu, X., Zhao, L., Park, J. W., Willingham, M. C., & Cheng, S.-Y. (2014) · Neoplasia · doi:10.1016/j.neo.2014.08.003 · Cited by 47
Double-hit lymphomas: current paradigms and novel treatment approaches
Dunleavy, K. M. (2014) · Hematology · doi:10.1182/asheducation-2014.1.107 · Cited by 46
Novel approaches to glioma drug design and drug screening
Patil, S. A., Hosni-Ahmed, A., Jones, T. S., Patil, R., Pfeffer, L. M., & Miller, D. D. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.807248 · Cited by 46
BET-Inhibitors Disrupt Rad21-Dependent Conformational Control of KSHV Latency
Chen, H.-S., Leo, A. D., Wang, Z., Andrew, K., Hills, R., & Lieberman, P. M. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006100 · Cited by 46
Shen, Y., Milda, S., Li, G., Zheng, D., & Liu, L. (2017) · Scientific Reports · doi:10.1038/srep42646 · Cited by 47
Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression
Gao, Z., Yuan, T., Zhou, X., Ni, P., Sun, G., Li, P., Cheng, Z., & Wang, X. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1423923 · Cited by 46
Bruyer, A., Maes, K., Herviou, L., Kassambara, A., Seckinger, A., Cartron, G., Reme, T. X., Robert, N., Requirand, G., Boireau, S., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0025-x · Cited by 48
Perry, J. A., Seong, B. K. A., & Stegmaier, K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055710 · Cited by 42
Lim, S. L., Damnernsawad, A., Shyamsunder, P., Chng, W. J., Han, B., Xu, L., Pan, J., Dakle, P., Alkan, S., Tyner, J. W., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.201483 · Cited by 46
SEanalysis: a web tool for super-enhancer associated regulatory analysis
Qian, F., Li, X., Guo, J., Zhao, J., Li, Y., Tang, Z., Zhou, L., Zhang, J., Bai, X., Jiang, Y., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz302 · Cited by 46
Jiang, Y., Hu, T., Wang, T., Shi, X. E., Kitano, A., Eagle, K., Hoegenauer, K. A., Konopleva, M. Y., Lin, C. Y., Young, N. L., et al. (2019) · Blood · doi:10.1182/blood.2019001076 · Cited by 47
Self-citationEndoplasmic reticulum stress actively suppresses hepatic molecular identity in damaged liver
Dubois, V., Gheeraert, C., Vankrunkelsven, W., Dubois‐Chevalier, J., Dehondt, H., Bobowski‐Gerard, M., Vinod, M., Zummo, F. P., Güiza, F., Ploton, M., et al. (2020) · Molecular Systems Biology · doi:10.15252/msb.20199156 · Cited by 46
Zhang, N., Mendieta-Esteban, J., Magli, A., Lilja, K. C., Perlingeiro, R. C. R., Martı́-Renom, M. A., Tsirigos, A., & Dynlacht, B. D. (2020) · Nature Communications · doi:10.1038/s41467-020-19999-w · Cited by 49
MED12 and BRD4 cooperate to sustain cancer growth upon loss of mediator kinase
Sooraj, D., Sun, C. X., Doan, A., Garama, D. J., Dannappel, M., Zhu, D., Chua, H. K., Mahara, S., Hassan, W. A. W., Tay, Y. K., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.11.015 · Cited by 46
Li, W., Yang, S., Xu, P., Zhang, D., Tong, Y., Chen, L., Jia, B., Li, A., Lian, C., Ru, D., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103861 · Cited by 46
Impact of the gut microbiota on enhancer accessibility in gut intraepithelial lymphocytes
Semenkovich, N. P., Planer, J. D., Ahern, P. P., Griffin, N. W., Lin, C. Y., & Gordon, J. I. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617793113 · Cited by 45
Self-citationSenescent cells limit p53 activity via multiple mechanisms to remain viable
Sturmlechner, I., Sine, C. C., Jeganathan, K. B., Zhang, C., Velasco, R. O. F., Baker, D. J., Li, H., & van Deursen, J. M. (2022) · Nature Communications · doi:10.1038/s41467-022-31239-x · Cited by 45
Chromatin regulation of transcriptional enhancers and cell fate by the Sotos syndrome gene NSD1
Sun, Z., Lin, Y., Islam, M. T., Koche, R. P., Hedehus, L., Liu, D., Huang, C., Vierbuchen, T., Sawyers, C. L., & Helin, K. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.06.007 · Cited by 45
Liau, W., Tan, S. H., Ngoc, P. C. T., Wang, C. Q., Tergaonkar, V., Feng, H., Gong, Z., Osato, M., Look, A. T., & Sanda, T. (2016) · Leukemia · doi:10.1038/leu.2016.392 · Cited by 47
Enhancer dysfunction in leukemia
Bhagwat, A. S., Lu, B., & Vakoc, C. R. (2018) · Blood · doi:10.1182/blood-2017-11-737379 · Cited by 45
Self-citationCREB Promotes Beta Cell Gene Expression by Targeting Its Coactivators to Tissue-Specific Enhancers
de Velde, S. V., Wiater, E., Tran, M. A., Hwang, Y., Cole, P. A., & Montminy, M. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00200-19 · Cited by 42
Luna-Peláez, N., March‐Díaz, R., Ceballos-Chávez, M., Guerrero-Martinez, J. A., Grazioli, P., García‐Gutiérrez, P., Vaccari, T., Massa, V., Reyes, J. C., & García‐Domínguez, M. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1792-x · Cited by 44
Zhang, Y., Zhou, L., Bandyopadhyay, D., Sharma, K., Allen, A. J., Kmieciak, M., & Grant, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3788 · Cited by 45
VARAdb: a comprehensive variation annotation database for human
Pan, Q., Liu, Y.-J., Bai, X., Han, X., Jiang, Y., Ai, B., Shi, S.-S., Wang, F., Xu, M., Wang, Y., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa922 · Cited by 45
Prominent Role of Histone Modifications in the Regulation of Tumor Metastasis
Markouli, M., Strepkos, D., Basdra, E. K., Papavassiliou, A. G., & Piperi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052778 · Cited by 48
Takayama, K., Kosaka, T., Suzuki, T., Hongo, H., Oya, M., Fujimura, T., Suzuki, Y., & Inoue, S. (2021) · Nature Communications · doi:10.1038/s41467-021-23974-4 · Cited by 45
Liu, Y., Wu, Z., Zhou, J. R., Ramadurai, D. K. A., Mortenson, K. L., Aguilera-Jimenez, E., Yan, Y., Yang, X., Taylor, A. M., Varley, K. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27055-4 · Cited by 44
Hilton, J. F., Cristea, M. C., Postel-Vinay, S. C., Baldini, C., Voskoboynik, M., Edenfield, W. J., Shapiro, G. I., Cheng, M. L., Vuky, J., Corr, B. R., et al. (2022) · Cancers · doi:10.3390/cancers14174079 · Cited by 45
Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis
Wu, F., Xu, L., Tu, Y., Cheung, O. K.-W., Szeto, L. L. M., Mok, M. T. S., Yang, W., Kang, W., Cao, Q., Lai, P. B. S., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.039 · Cited by 45
Identification and functional validation of super-enhancers in Arabidopsis thaliana
Zhao, H., Yang, M., Bishop, J., Teng, Y., Cao, Y., Beall, B. D., Li, S., Liu, T., Fang, Q., Fang, C. Q., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2215328119 · Cited by 45
A phenotypic screening platform for identifying chemical modulators of astrocyte reactivity
Clayton, B. L. L., Kristell, J. D., Allan, K. C., Cohn, E. F., Karl, M. T., Jerome, A. D., Garrison, E. D., Maeno-Hikichi, Y., Sturno, A. M., Kerr, A., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01580-z · Cited by 43
Gene activation by metazoan enhancers: Diverse mechanisms stimulate distinct steps of transcription
Beagrie, R. A., & Pombo, A. (2016) · BioEssays · doi:10.1002/bies.201600032 · Cited by 44
Su, J., Liu, X., Zhang, S., Yan, F., Zhang, Q., & Chen, J. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1317666 · Cited by 44
Enssle, J. C., Boedicker, C., Wanior, M., Vogler, M., Knapp, S., & Fulda, S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.032 · Cited by 44
Transcriptional and epigenetic regulation of immune tolerance: roles of the NF-κB family members
Zhang, L., Xiao, X., Arnold, P. R., & Li, X. C. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0202-8 · Cited by 45
The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation
Chatonnet, F., Pignarre, A., Sérandour, A. A., Caron, G., Avner, S., Robert, N., Kassambara, A., Laurent, A., Bizot, M., Agirre, X., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.222133 · Cited by 44
Inhibition of super enhancer downregulates the expression of KLF5 in basal-like breast cancers
Chen, C., Yang, N., Zhang, Y., Ding, J., Zhang, W., Liu, R., Liu, W., & Chen, C. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.35138 · Cited by 44
Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma
Song, S., Li, Y., Xu, Y., Ma, L., Pizzi, M. P., Jin, J., Scott, A. W., Huo, L., Wang, Y., Lee, J. H., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12667 · Cited by 44
Barrows, D., Feng, L., Carroll, T. S., & Allis, C. D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2008017117 · Cited by 44
Cui, H., Carlson, A. S., Schleiff, M. A., Divakaran, A., Johnson, J. A., Buchholz, C. R., Zahid, H., Vail, N. R., Shi, K., Aihara, H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00933 · Cited by 44
Alvarez-Benayas, J., Trasanidis, N., Katsarou, A., Ponnusamy, K., Chaidos, A., May, P. C., Xiao, X., Bua, M., Atta, M. L. B. S., Roberts, I. A. G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25704-2 · Cited by 50
A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes
Cui, H., Divakaran, A., Hoell, Z. J., Ellingson, M. O., Scholtz, C. R., Zahid, H., Johnson, J. A., Griffith, E. C., Gee, C. T., Lee, A. L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01779 · Cited by 45
Chayka, O., D’Acunto, C. W., Middleton, O., Arab, M., & Sala, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.624056 · Cited by 44
Impaired DNA demethylation of C/EBP sites causes premature agingPreprint
Schäfer, A., Mekker, B., Mallick, M., Vastolo, V., Karaulanov, E., Sebastian, D., von der Lippen, C., Epe, B., Downes, D. J., Scholz, C., et al. (2018) · Genes & Development · doi:10.1101/gad.311969.118 · Cited by 42
Gusyatiner, O., Bady, P., Pham, M. D. T., Lei, Y. Y., Park, J., Daniel, R. T., Delorenzi, M., & Hegi, M. E. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab115 · Cited by 43
Therapeutic Targets in Diffuse Midline Gliomas—An Emerging Landscape
Hayden, E., Holliday, H., Lehmann, R. J., Khan, A., Tsoli, M., Rayner, B. S., & Ziegler, D. S. (2021) · Cancers · doi:10.3390/cancers13246251 · Cited by 42
Hemming, M. L., Benson, M. R., Loycano, M. A., Anderson, J. A., Andersen, J. L., Taddei, M. L., Krivtsov, A. V., Aubrey, B. J., Cutler, J. A., Hatton, C., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0646 · Cited by 39
Blum, K. A., Supko, J. G., Maris, M. B., Flinn, I. W., Goy, A. H., Younes, A., Bobba, S., Senderowicz, A. M., Efuni, S., Rippley, R. K., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0060 · Cited by 43
Cross-lineage potential of Ascl1 uncovered by comparing diverse reprogramming regulatomes
Wang, H., Keepers, B., Qian, Y., Xie, Y., Colon, M., Liu, J., & Li, Q. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.09.006 · Cited by 46
Characterization of BRD4 during Mammalian Postmeiotic Sperm Development
Bryant, J. M., Donahue, G., Wang, X., Meyer‐Ficca, M. L., Luense, L. J., Weller, A. H., Bartolomei, M. S., Blobel, G. A., Meyer, R. G., Garcia, B. A., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01328-14 · Cited by 43
Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma
Dupéré-Richer, D., & Licht, J. D. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000358 · Cited by 43
Metadata
- Authors
- Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A.
- Affiliations
- Whitehead Institute for Biomedical Research (US)
- Dana-Farber Cancer Institute (US)
- Cold Spring Harbor Laboratory (US)
- Harvard University (US)
- Corresponding author
- Young, Richard A.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2013-04
- Volume
- 153
- Issue
- 2
- Pages
- 320-334
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC3760967
- OpenAlex
- W1523117612
- Cited by
- 2,961
- References
- 86
- Citations by year
- 2026: 140 · 2025: 214 · 2024: 261 · 2023: 254 · 2022: 271 · 2021: 327 · 2020: 263 · 2019: 248 · 2018: 218 · 2017: 205 · 2016: 184 · 2015: 175 · 2014: 143 · 2013: 53
- FWCI
- 83.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- National Institutes of Health (5p30ca045508-35)
- National Human Genome Research Institute (HG002668, R01HG002668)
- National Cancer Institute (CA146445, R01CA146445, P30-CA045508, CA45508, P30CA014051)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- super-enhancers, BRD4, MYC oncogene, multiple myeloma, BET inhibitors, JQ1, Mediator complex, transcriptional coactivator, transcription elongation, chromatin regulators, cancer therapy, enhancer disruption
- MeSH terms
- Bromodomain Containing Proteins, Antineoplastic Agents, Azepines, Chromatin, Enhancer Elements, Genetic, Humans, Multiple Myeloma, Neoplasms, Nuclear Proteins, Transcription Factors, Transcription, Genetic, Triazoles, Gene Expression Regulation, Neoplastic, Cell Cycle Proteins, Cell Line, Tumor, Genome-Wide Association Study, Mediator Complex, Transcription Elongation, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
